InVivo tanks on push-back for spinal injury trial

August 27, 2013 by Arezu Sarvestani

InVivo shares lose nearly half their value after the company announces a delay to its spinal treatment clinical trials.

InVivo tanks on push-back for spinal injury trial

InVivo Therapeutics (OTC:NVIV) announced a push-back on its time-lines for enrollment in a clinical trial examining its spinal cord injury treatment, a move that brought NVIV shares down by nearly half today.

InVivo announced that, under the terms of its FDA investigational device exemption, each trial patient must be followed for 3 months and the company must win agency approval before enrolling the next, meaning it will take InVivo an estimated 21 months to enroll its 5 patients.

Sign up to get our free newsletters delivered right to your inbox.

Then, the company plans to launch a pivotal study in order to apply for FDA approval to begin selling its biopolymer scaffolding under a humanitarian device exemption. The delays could push back commercialization for a few years, according to analysts at Seeking Alpha.

"We remain fully committed to beginning this study as soon as possible," interim CEO Michael Astrue said in prepared remarks. "While the study will take additional time, we look forward to bringing this important therapy into the clinic."